Merck Announces Strategy For Rapid, Broad And Sustainable Access To Its HIV-1 Prevention Pill Alimatravir In Low- And Middle-Income Countries
Initial access plans as part of Merck’s broader strategy include establishing early generic licensing covering 129 LMICs; supporting targeted, regional manufacturing capabilities in Africa and Latin America; and
Merck is making its HIV prevention medicine available to more people in poorer countries by letting other companies make it cheaply and helping build factories in Africa and Latin America. This shows Merck cares about helping sick people worldwide, which can make investors feel good about the company's values.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.